Isotol inhalation is used in patients

What is ISOTOL?

Isotol inhalation is used in patients 6 years of age and older to help diagnose asthma. It is used in a procedure called a bronchial provocation test to help your doctor measure the effect of this medicine on your lungs and to check if you are having trouble breathing.


Isotol inhalation is also used as add-on maintenance therapy to improve lung function in cystic fibrosis patients. Before using Isotol®, your doctor will perform an Isotol® Tolerance Test (BTT).


Isotol™ should only be used by or under the direct supervision of your doctor.


Isotol® is only for use in patients who have passed the Isotol® Tolerability Test (BTT). Do not use this medicine if you fail the BTT.

Isotol, the active ingredient in Isotol (Isotol inhalation powder), is a sugar alcohol indicated for the evaluation of bronchial hyperresponsiveness in patients 6 years of age or older without clinically apparent asthma.

Isotol (Isotol Inhalation Powder) is not a stand-alone test or an asthma screening test. A bronchial provocation test with Isotol (Isotol inhalation powder) should only be used as part of a physician’s

How should I use ISOTOL?

Isotol is for oral inhalation only.

Do not use Isotol until your healthcare provider has given you BTT and approved you for treatment. If you have any questions, please consult your healthcare provider or pharmacist.

Use Isotol exactly as your healthcare provider tells you to.

Do not swallow Isotol capsules. Isotol capsules should only be used with the inhaler device provided.

Isotol is a test kit containing the required capsules of dry powder Isotol for oral inhalation in graduated doses with the supplied single patient use inhaler necessary to perform one bronchial challenge test. The inhaler should be discarded after use.

Do not swallow Isotol (Isotol inhalation powder) capsules.

The airway response to bronchial challenge testing with Isotol (Isotol inhalation powder) is measured using forced expiratory volume in one second (FEV.

Patients with either a positive response to bronchial challenge testing with Isotol (Isotol inhalation powder) or significant respiratory symptoms should receive a standard dose of a short acting inhaled beta-agonist and monitored until fully recovered to within baseline.

Leave a Reply